Evidence map›Paper›PMID 42765004›Full record

ReviewActa pharmaceutica Sinica. B2026

Nanomaterial-driven spatiotemporal autophagy modulation: The dual-edged sword in precision cancer therapy.

Linghuan Xu, Jintao Hao, Yueyang Zhao, Yanshu Wang, Yuetong Yu, Chaoxing He, Zhiyun Niu, Defang Ouyang, Bai Xiang

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linghuan XuDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Jintao HaoDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Yueyang ZhaoDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Yanshu WangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Yuetong YuDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Chaoxing HeDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.
Zhiyun NiuDepartment of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Defang OuyangState Key Laboratory of Mechanism and Quality in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau 999078, China.
Bai XiangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autophagy-modulating nanomaterials have emerged as a promising therapeutic paradigm in oncology, offering precise intervention in tumor progression, metastasis, and treatment resistance. The therapeutic efficacy of these platforms is largely attributed to their context-dependent dual functionality. On one hand, they are capable of inducing cytotoxic autophagy, such as through the activation of oxidative stress or endoplasmic reticulum stress, leading to tumor cell death. On the other hand, they can inhibit cytoprotective autophagy, a crucial survival mechanism exploited by tumor cells, by impairing lysosomal function or perturbing cellular energy metabolism. A key advancement in this field is the ability of nanomaterials to achieve spatiotemporal control over autophagy modulation, allowing targeted regulation at specific tumor sites and disease stages. This review systematically summarizes the molecular mechanisms underlying these bidirectional effects, with particular emphasis on the modulation of selective autophagy pathways including mitophagy, and discusses how rational nanomaterial design adapted to tumor stage and microenvironment dictates therapeutic outcomes. Finally, we highlight major translational challenges, especially the lack of standardized characterization and the difficulty in precisely controlling autophagic responses, which must be addressed to facilitate the clinical translation of these innovative nanotherapeutic strategies.

Indexed as

Autophagy modulationCancer therapyClinical translationDual roleNanomaterialsSelective autophagySpatiotemporal controlTumor microenvironment

Identifiers

PMID42765004
PMCPMC13589957

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.